康方生物：中国创新药的“Deepseek时刻”或将到来

Core Insights - Kangfang Biopharma's innovative bispecific antibody drug AK112 has gained global attention after outperforming the leading drug K drug in head-to-head trials, with plans to submit a market application in the U.S. [1] - The company has secured an overseas licensing upfront payment of approximately $500 million [1] - In Q1 of this year, Chinese pharmaceutical companies completed 33 overseas licensing deals totaling $36.6 billion, marking a 258% year-on-year increase [1] - Leading companies such as Kangfang Biopharma, 3SBio, and CSPC Pharmaceutical Group are making significant progress in the international market [1] - The "Deepseek moment" for Chinese innovative drugs is anticipated to arrive soon [1]